Skip to main navigation
Ascendis Pharma Logo
  • Overview
  • Events & Presentations
  • News Releases
    • For Global Media Only
    • For U.S. Media Only
  • Corporate Governance
    • Corporate Governance Documents & Charters
    • Leadership
    • Committee Composition
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
  • Financial & Filings
    • Quarterly Reports
    • SEC Filings
    • Annual General Meeting
    • Extraordinary General Meeting
      • Sept. 9, 2022 EGM
      • Nov. 18, 2021 EGM

Events & Presentations

Events & Presentations

Upcoming Events

November 12, 2026 at 8:00 AM EST
Q3 2026 Ascendis Pharma Earnings Conference Call
Click Here for Webcast
Add to Outlook
Add to Google Calendar

Presentations

August 6, 2026
COACH Week 78 and Achondroplasia Program Update
July 8, 2026
ICCBH 2026: Radiographic Data from Week 104 ApproaCH Trial
June 13, 2026
ENDO 2026: Week 182 PaTHway Data
June 11, 2026
5-Year PaTH Forward Results
May 6, 2026
PES 2026 ApproaCH 2-Year Subgroup Data
April 8, 2026
New Data: Phase 2 COACH Trial Week 52
March 16, 2026
ACMG 2026: ApproaCH Week 104 Data
March 2, 2026
YUVIWEL® (navepegritide) FDA Approval
January 9, 2026
44th Annual J.P. Morgan Healthcare Conference Presentation
January 8, 2026
COACH Trial Topline Week 52 Data

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page next ›
  • Last page last »

Shareholder Tools

RSS Feeds
Email Alerts
IR Contact

Footer Corporate Menu

  • TransCon
  • About us
  • Pipeline
  • Patients
  • Investors & News
  • Contact Us

Footer Copyrights Menu

  • Privacy Policy
  • Terms of Use
Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group
© November 2026 Ascendis Pharma